newsfilter
← Latest News
GlobeNewswire·

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated